CRTX was granted a US patent for “Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same”.
Sometimes catalysts don’t come in the form of formal news releases. Based on this, it’s essential to have your ear to the ground and pay close attention to anything that could impact certain companies. When we talk about biotech, everything from FDA decisions to patent updates can affect a stock.
Clarus was moving thanks to this patent news. Here are some of the details that emerged early on but have yet to be formally reported in a company press release. For complete information from the US Patent and Trademark Office, you can follow this link:
I think there is still time to enter this position - even after the big run up today
Truist joined Needham, Maxim, Oppenheimer, and Cantor Fitzgerald, all having a Buy or equivalent and price targets ranging from $12 to $20.
Furthermore, with a total outstanding share count of less than 22 million right now
Will be looking for an entry point and will dive deeper into the company so keep an eye out for updates to this analysis